Our Company Our Focus Our Science Join Us New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Our Company Our Focus Our Science Join Us New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Basel, November 11, 2018 Novartis announced today results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto tablets provided superior benefit compared to enalapril-a heart failure medication commonly used-in patients with HFrEF who had been stabilized following admission for an acute decompensation heart failure (ADHF) event[1]. Results were presented as a late-breaker at the American Heart Association’s Scientific Sessions 2018 and published in The New England Journal of Medicine.
November 13, 2018 / Pharma News